Company
Company description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.
Quick Presentation Filters

Filter

      Loading ...

      Loading ...

      Loading ...

Filter

      Loading ...

      Loading ...

      Loading ...

Presentations (1)
Investor Presentation
September 2022
24 slides
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2024 Slidebook.io